Dronedarone Lipid Capsule Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antiarrhythmic compounds like dronedarone and amiodarone have low solubility in aqueous mediums, particularly in the intestinal environment, leading to poor bioavailability and requiring specific administration conditions, such as being taken with meals, which limits their therapeutic flexibility.
Innovation Solution
A pharmaceutical composition comprising a benzofuran derivative, such as dronedarone, combined with an amphiphilic lipid excipient with an HLB value between 5 and 18, formulated in a semi-solid or liquid capsule form, which enhances solubility and stability in the gastrointestinal tract, allowing for administration on an empty stomach or with a light meal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiarrhythmic compounds like dronedarone are used in conventional formulations, then therapeutic effect is achieved, but solubility in aqueous medium is low leading to poor bioavailability
Solution Approach 1:
The patent introduces lipid excipients (medium-chain triglycerides, long-chain triglycerides, or their mixtures) as intermediary substances to solubilize dronedarone. These lipids act as mediators between the hydrophobic active ingredient and the aqueous gastrointestinal environment, enabling dronedarone to be dissolved in lipid vehicles that can then be absorbed and transported in the body, thereby resolving the solubility-bioavailability contradiction
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by using lipid-based excipients with specific properties (medium-chain or long-chain triglycerides, alone or in combination). This parameter change transforms the formulation from a conventional water-based system to a lipid-based system, fundamentally altering the solubility characteristics and enabling dronedarone to maintain therapeutic concentrations in the gastrointestinal tract and plasma
2Adaptability or versatility
If dronedarone is administered in conventional form, then treatment is effective, but administration conditions are restricted requiring intake with meals
Solution Approach 1:
The lipid excipient formulation acts as an intermediary system that decouples drug absorption from meal intake. The lipid vehicle maintains dronedarone in solution throughout the gastrointestinal tract regardless of food presence, eliminating the need for meal-dependent administration and thereby improving both administration flexibility and ease of operation
3Adaptability or versatility
If dronedarone is administered without meals, then administration flexibility is improved, but bioavailability decreases due to precipitation in intestinal environment
Solution Approach 1:
The lipid excipient serves as a protective intermediary that prevents dronedarone precipitation in the intestinal environment. By maintaining the drug in a lipid-based solution rather than exposing it directly to aqueous intestinal fluids, the formulation ensures consistent bioavailability whether administered with or without meals, thereby resolving the contradiction between flexibility and reliability
Solution Approach 2:
The patent changes the formulation parameters by using lipid-based excipients that maintain drug solubility across different gastrointestinal conditions. This parameter change ensures that dronedarone remains in solution during intestinal transit regardless of meal intake, maintaining reliable bioavailability while enabling flexible administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition ensures sustained release and improved bioavailability of the active ingredient, reducing the meal effect and maintaining therapeutic efficacy regardless of food intake, thereby providing greater flexibility in administration.
Implementation Method 1
The composition ensures sustained release and improved bioavailability of the active ingredient... comprising at least one benzofuran derivative, such as dronedarone, combined with an amphiphilic lipid excipient with an HLB value between 5 and 18, formulated in a semi-solid or liquid capsule form, which enhances solubility and stability in the gastrointestinal tract
Data Source
AI summary
The invention generally relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in a dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal effect following oral administration in humans. The lipid carrier allows: the solubilisation of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.